Evidence map›Paper›PMID 24999606›Full record

ArticlePharmaceutics2014

Release of tenofovir from carrageenan-based vaginal suppositories.

Toral Zaveri, John E Hayes, Gregory R Ziegler

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. On-demand microbicide products: design matters.Drug delivery and translational research · 2017
    Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Toral ZaveriSensory Evaluation Center, the Pennsylvania State University, University Park, PA 16802, USA. tzz1@psu.edu.
John E HayesSensory Evaluation Center, the Pennsylvania State University, University Park, PA 16802, USA. jeh40@psu.edu.
Gregory R ZieglerDepartment of Food Science, College of Agricultural Sciences, the Pennsylvania State University, 341 Food Science Building, University Park, PA 16802, USA. grz1@psu.edu.
Pennsylvania State University · US

Funding

Designing Optimal Microbicide Delivery Integrating Rheology and AcceptabilityR33AI094514 · NIAID · PENNSYLVANIA STATE UNIVERSITY, THE · PI HAYES, JOHN EDWARD · 2013 to 2015
$1.3M
Designing optimal microbicide delivery integrating rheology and acceptabilityR21AI094514 · NIAID · PENNSYLVANIA STATE UNIVERSITY, THE · PI HAYES, JOHN EDWARD, ZIEGLER, GREGORY RAY · 2011 to 2012
$390k
NIAID NIH HHS R21 AI094514NIAID NIH HHS R33 AI094514
6 · The paper itself

Abstract

Microbicides are an active area of research for HIV prevention, being developed as a woman-initiated method of prevention during unprotected coitus. Along with safety and efficacy, assessing and improving compliance is a major area of research in microbicide development. We have produced microbicide prototypes in the form of semisoft vaginal suppositories prepared from carrageenan and conducted both qualitative and quantitative studies using these prototypes to determine the physical properties that drive acceptability and possibly adherence. In order to ensure that the suppositories function as effective drug delivery vehicles, we have conducted in vitro dissolution studies in water, vaginal simulant fluid (VSF) and semen simulant fluid (SSF) with suppositories loaded with the antiretroviral drug, tenofovir (TFV). TFV was released via diffusion and matrix erosion in water or by diffusion out of the matrix in VSF and SSF. Diffusion studies were conducted in two different volumes of VSF and SSF. The volume of VSF/SSF into which TFV diffused and the size of the suppositories determined the rate of diffusion from the suppositories. About 45%-50% of the encapsulated TFV diffused out of the suppositories within the first two hours, irrespective of suppository size, diffusion medium (VSF/SSF) and the volume of medium. Prior work indicates that a short waiting period between insertion and coitus is highly desired by women; present data suggest our microbicide prototypes have rapid initial release followed by a slow release curve over the first 24 h.

Identifiers

PMID24999606
PMCPMC4190525
OpenAlexW2066035441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.